Endocyte (ECYT) News Today → get a piece of the profit from this land (From True Market Insiders) (Ad) Free ECYT Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share HeadlinesStock Analysis All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative February 16, 2024 | investing.comTelix Pharmaceuticals Ltd (TLX)January 3, 2024 | fool.com.au'The most exciting company in Australia': The ASX stock up 179% in 6 monthsMay 17, 2023 | thestreet.comThe Endocyte Bear Thesis: Why March Will be a Bad MonthJanuary 5, 2023 | thestreet.comWhy Endocyte (ECYT) Stock Is Plummeting in After-Hours Trading TodaySeptember 20, 2022 | finance.yahoo.comGlobal Pharmaceutical Contract Manufacturing Market is projected to reach a market value of US$329.7 Billion in 2032: Visiongain Reports Ltd - Yahoo FinanceJune 6, 2022 | globenewswire.comPurdue University impacting lives: successfully delivering innovations to the public - GlobeNewswireMay 23, 2022 | globenewswire.comGlobal Chronic Myeloid Leukemia Pipeline Insight | Clinical Trials Evaluation Research Report 2022 by DelveInsight - GlobeNewswireMay 20, 2022 | benzinga.comCortexyme Appoints Dr. Philip Low to Its Board of Directors - Benzinga - BenzingaMay 20, 2022 | streetinsider.comCortexyme (CRTX) Appoints Philip Low to Its Board - StreetInsider.comMay 3, 2022 | nasdaq.comNovartis Is Looking for Deals. Are These 3 Biotechs on Its List? - NasdaqApril 25, 2022 | seekingalpha.comClovis: Shifting Toward Nuclear Medicine - Seeking AlphaApril 14, 2022 | globenewswire.comGlobal Pharmaceutical Contract Manufacturing Market is projected to reach a market value of US$329.7 Billion in 2032: Visiongain Research Inc - GlobeNewswireJanuary 31, 2022 | globenewswire.comNon-Muscle Invasive Bladder Cancer Pipeline Insights | Clinical Trials Report 2022 by DelveInsight - GlobeNewswireJanuary 27, 2022 | finance.yahoo.comGlobal Oncology Radiopharmaceuticals Market to Surpass US$ 5,206.8 Million by 2028, Says Coherent Market Insights (CMI) - Yahoo FinanceDecember 19, 2021 | proactiveinvestors.com.auRadiopharm Theranostics enhances management team skillset with three key appointments - Proactive Investors AustraliaNovember 2, 2021 | finance.yahoo.comFusion Pharmaceuticals Appoints Industry Veteran Christopher Leamon, Ph.D., as Chief Scientific Officer - Yahoo FinanceNovember 2, 2021 | streetinsider.comFusion Pharmaceuticals Inc. (FUSN) Appoints Christopher Leamon as Chief Scientific Officer - StreetInsider.comSeptember 20, 2021 | streetinsider.comMirati Therapeutics (MRTX) Appoints David Meek as CEO - StreetInsider.comAugust 16, 2021 | afr.comTelix Pharma is on the cusp of first US FDA approval - The Australian Financial Review Get Endocyte News Delivered to You Automatically Sign up to receive the latest news and ratings for ECYT and its competitors with MarketBeat's FREE daily newsletter. Email Address get a piece of the profit from this land (Ad)This isn’t the prettiest land on earth. But it might be the most valuable. And you don’t have to own, lease, or rent any land. Click here to see my #1 investment for 2024. ECYT Media Mentions By Week ECYT Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ECYT News Sentiment▼0.000.50▲Average Medical News Sentiment ECYT News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ECYT Articles This Week▼00▲ECYT Articles Average Week Get Endocyte News Delivered to You Automatically Sign up to receive the latest news and ratings for ECYT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: SUPN News CORT News PCRX News PRGO News JAZZ News SNDX News EWTX News NAMS News AMRX News GLPG News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ECYT) was last updated on 5/18/2024 by MarketBeat.com Staff From Our PartnersObama’s Forever Term [exposed]Porter & CompanyCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingThe Overlooked Retirement Asset You Probably Don’t OwnCrypto 101 Media4 Cryptos BETTER than BitcoinTrue Market InsidersMissed NVDA? Buy this AI stock NOWChaikin AnalyticsUrgent Nvidia WarningAltimetryMost important medical advance in 100 yearsThe Oxford ClubNext President (Not Trump. Not Biden.)The Freeport Society Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Endocyte, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.